Hox and Vernalis announce a drug discovery collaboration in oncology
Vernalis Research, a fully owned subsidiary of Chinese firm HitGen Inc., and US-based Unison Medicines Inc. have announced a research collaboration on an undisclosed bacterial target.
Vernalis Research (Vernalis), a fully owned subsidiary of HitGen Inc., and Unison Medicines Inc. (Unison), a discovery stage pharmaceutical company, have announced a research collaboration on an undisclosed bacterial target.
The founder of a biotech bought by Gilead Sciences has birthed another startup. Dania Therapeutics begins life with a discovery program based on Kristian Helin’s work and plans to advance small-molecule inhibitors of new oncology targets.
CHENGDU, China--(BUSINESS WIRE)--Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Hannibal Innovation ApS (“Hannibal”) are pleased to announce the creation of Dania Therapeutics ApS (“Dania”) to discover small molecules inhibitors against new undisclosed oncology targets.